FPOLayout for review — draft content, for placement only. Imagery and claims shown from global material pending Canadian adaptation. Ghosted items show the future full website.
PrFREHEMGO®denecimig injectionMy profileFPOENFR

FREEDOM* FROM BLEEDS
WITH A ONCE-MONTHLY PEN1

Normalise thrombin generation** and FVIII bioequivalence with the next-generation, ultra-potent† FVIIIa mimetic1–5FPO
Roman lives with hemophilia AFPO
FREHEMGO® pen (46 mg)FPO

FREHEMGO® is indicated for routine prophylaxis of bleeding episodes in patients with hemophilia A (congenital coagulation FVIII deficiency) with or without FVIII inhibitors1

FREHEMGO® is the only†† once-monthly, ultra-potent‡ HA PPx that offers:1–4,6

TG chartFPO

Normal levels all month long

Normalised thrombin generation, FVIII bioequivalence and clot structure all month long. FPO

Discover the innovation
Study imageryFPO

The freedom* of zero bleeds

Halved bleed rates vs FVIII PPx and a mean ABR of just 0.7, freeing 90% of patients from spontaneous bleeds. FPO

Explore efficacy data
Pen line-upFPO

Administration made simple

Less than a mL, less than a minute and almost no injection pain with a preferred pen. FPO

Discover dosing

Contact us

Our Novo Nordisk representatives are here to help